Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human immunodeficiency virus 1

ABSTRACT: Phase-I trial of broadly neutralizing anti-HIV-1 antibody 10-1074

PROVIDER: PRJNA356756 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5105400_1.fastq.gz	Fastqsanger.gz
	SRR5105400_2.fastq.gz	Fastqsanger.gz
	SRR5105420_1.fastq.gz	Fastqsanger.gz
	SRR5105420_2.fastq.gz	Fastqsanger.gz
	SRR5105960_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

HIV-Induced Sialoglycans on Infected Cells Promote Immune Evasion from Myeloid Cell-Mediated Killing

Project description:Sialic acid-containing glycans (sialoglycans) on pathological cells interact with Siglecs, glyco-immune checkpoint receptors expressed on myeloid cells such as monocytes and neutrophils. This interaction suppresses the cytotoxic functions of these immune cells. We show that HIV infection reprograms the glycosylation machinery of infected cells to increase the expression of specific sialoglycan ligands for Siglecs-3, -7, and -9. These ligands engage Siglecs on myeloid cells, impairing their ability to target HIV-infected cells. Selective disruption of these interactions using 10-1074-Sia, an HIV-specific antibody conjugated to sialidase—an enzyme that removes sialic acids—significantly enhances monocyte- and neutrophil-mediated killing of HIV-infected cells in autologous assays. Treatment with 10-1074-Sia in humanized mice infected with HIV reduces viral load and decreases inflammation. These findings reveal a novel immune evasion mechanism exploited by HIV to evade myeloid cell immune surveillance and highlight the potential of targeting sialoglycan-Siglec interactions to improve immune clearance of HIV-infected cells.

2025-10-13 | GSE289893 | GEO

Human immunodeficiency virus 1 strain:HXB2

Project description:Anti-HIV-1 CAR-T cells armed with autogenic broadly neutralizing antibody and follicle-homing receptor CXCR5 ar effective against different HIV-1 clades and reduce viral reservoir in HIV-1-infected individuals

| PRJNA903552 | ENA

Determinants of successful AAV delivery of HIV-1 bNAbs in early life

Project description:A single AAV vector dose delivering broadly neutralizing antibody 3BNC117 at birth provided over 3 years of protection against HIV-like infection in infant rhesus macaques. Neonatal administration was most effective due to immune tolerance, which reduced anti-drug antibodies and enabled sustained bNAb expression. This approach offers a promising one-time gene therapy strategy to prevent perinatal and adolescent HIV-1 infections. A total of 65 rhesus macaques (Macaca mulatta) of Indian origin were utilized in this study

2025-09-30 | GSE301418 | GEO

Human immunodeficiency virus 1

Project description:Broad neutralizing HIV antibodies

| PRJNA294363 | ENA

Smart-seq2 data from memory B cells from an individual living with HIV with broadly neutralizing plasma and an individual living with HIV who is aviremic without treatment

Project description:Tissue-like memory, activated memory and resting memory B cells were sorted by FACS from the individual living with HIV (EC17) who was aviremic and transcriptomes generated using the SmartSeq2 protocol. This was to provide a reference set for each memory B cell subset in the context of HIV. Next, HIV-specific memory B cells from the individual with broadly neutralizing plasma were then also sorted by FACS and single cell transcriptomes generated using the SmartSeq2 protocol. The phenotypes of memory B cells from the individual with broadly neutralizing plasma (T125) were then inferred from the reference set using Glmnet and Celltypist packages.

2023-12-24 | E-MTAB-13592 | biostudies-arrayexpress

Homo sapiens

Project description:Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

| PRJNA202933 | ENA

Vaccination with an mRNA-encoded membrane-bound HIV envelope trimer induces neutralizing antibodies in animal models

Project description:A protective vaccine against HIV will likely need to induce broadly neutralizing antibodies (bnAbs) that engage relatively conserved epitopes on the HIV envelope glycoprotein (Env) trimer. We report the design of mRNA-delivered membrane-bound form of a stabilized native-like Env trimer (BG505 MD39.3) and comprehensive evaluation of B cell, T cell, and antibody responses in non-human primates.

2025-07-30 | GSE298795 | GEO

Variability in the Glycosylation Patterns of gp120 Proteins from Different Human Immunodeficiency Virus Type 1 Isolates Expressed in Different Host Cells

Project description:The mature HIV-1 envelope (Env) glycoprotein is composed of gp120, the exterior subunit, and gp41, the transmembrane subunit assembled as trimer by noncovalent interaction. There is a great body of literature to prove that gp120 binds to CD4 first, then to the co-receptor. We have recently demonstrated that gp120 cannot bind to the co-receptor without first interacting with CD4. Previous studies provided different glycomic maps for the HIV-1 gp120. Here, we build on previous work to report that the use of LC-MS/MS, in conjunction with hydrophilic interaction liquid chromatography (HILIC) enrichment to glycosylation sites, is associated with the assorted neutralizing or binding events of glycosylation targeted antibodies from different clades or strains. In this study, the microheterogeneity of the glycosylation from 4 different clades of gp120s is deeply investigated. Aberrant glycosylation patterns were detected on gp120 originated from different clades, viral sequences and host cells. The results of this study may help provide better understanding of the mechanism of how the glycans participate in antibody neutralizing process that target glycosylation sites.

2021-11-01 | PXD027353 | Pride

HIV broadly neutralizing antibody precursors induced to the Apex epitope in non-human primates

Project description:HIV broadly neutralizing antibody precursors induced to the Apex epitope in non-human primates

| PRJNA1299323 | ENA

Project description:Longitudinal HIV-1 env sequencing in an individual with a broadly neutralizing antibody response

| PRJNA630482 | ENA